BioIntelliSense
Andrew Kwilasz is a seasoned professional with extensive experience in project management, technical research writing, and academia. Currently serving as a Project Manager and Technical Research Writer at BioIntelliSense, Inc. since June 2022, Andrew specializes in creating technical and regulatory documentation for innovative medical devices. In addition to this role, Andrew has been an Adjunct Assistant Professor and Research Associate at the University of Colorado Boulder since June 2013, managing a team to investigate gene therapies and developing new animal models for multiple sclerosis research. Previous roles include consulting on GLP toxicology studies at Xalud Therapeutics, technical writing at Samba Scientific, and adjunct teaching at Regis University. Andrew holds a Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University, complementing a Bachelor of Arts in Psychology from the University of Wisconsin-Eau Claire.
This person is not in the org chart
BioIntelliSense
1 followers
BioIntelliSense has enabled medical-grade Remote Patient Monitoring Hospital at Home (RPM-H@H) via its BioSticker-based data service. The BioSticker™ is an FDA-cleared 510k class II wearable medical device that enables at-home continuous monitoring of vital signs and symptoms directly associated with COVID-19 (temperature, respiratory rate at rest, and coughing frequency) for 30 days on a single device without recharging.